Clinical trials
Central Nervous System Tumor clinical trials
Below are recruiting central nervous system tumor clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06175000RecruitingPhase 2
Maintenance obinutuzumab for central nervous system lymphoma
This trial tests whether a maintenance drug called obinutuzumab can help prevent relapse in people with primary central nervous system lymphoma (a rare lymphoma in the brain or spine) who have already responded to initial chemotherapy. It is for those who have achieved at least a partial or complete response to their first treatment.
New York, New YorkAges 18 years+ - NCT06121336Recruiting
Tracking a blood marker to measure stroke recovery
This study is looking at a protein in the blood called brain-derived tau, which may increase after a stroke. By measuring it over time, doctors hope to learn more about how the brain is healing and possibly predict recovery.
Munich, BavariaAges 18 years+ - NCT06099743Recruiting
Support program for people with brain tumors
This study tests a support program that helps people with brain tumors cope with their diagnosis and treatment. The program uses acceptance and commitment therapy, which focuses on accepting difficult emotions and committing to actions that improve well-being.
Boston, MassachusettsAges 18 years+ - NCT06054295Recruiting
Twin study of childhood brain tumors
This study looks at genetic differences between identical twins where only one twin has a childhood brain or spinal cord tumor. It helps researchers understand why some children get cancer and others don't.
Minneapolis, MinnesotaAges Up to 18 years - NCT06026735Recruiting
Lung cancer with brain spread: a surgical study
This trial looks at people with non-small cell lung cancer that has spread to the brain or the membranes around the brain. It aims to learn more about patients who are already scheduled for brain surgery, such as removing a tumor or placing a drain.
TaipeiAges 20–90 - NCT05978557Recruiting
Brain tumor drug testing using live tissue samples
This trial uses a small piece of your brain tumor after surgery to test which drugs might work best for you. It helps doctors find the most effective treatment for your specific tumor.
Chapel Hill, North CarolinaAges Any age - NCT05931328RecruitingPhase 2
Thiotepa plus pomalidomide for recurrent brain lymphoma
This Phase 2 trial tests a combination medicine (thiotepa plus pomalidomide) for people whose primary central nervous system lymphoma has come back or did not respond to prior chemotherapy. It may help shrink lymphoma in the brain/spinal fluid and improve disease control.
Nanjing, JiangsuAges 18–75 - NCT05785039RecruitingPhase 2
Study drug for advanced bladder and other solid cancers
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05745623RecruitingPhase 1/Phase 2
Testing an NTRK-fusion drug for advanced tumors
This Phase 1/2 study tests ICP-723, a medicine designed to treat cancers that have an NTRK gene fusion. It may help shrink tumors in people whose cancer test shows this specific genetic change and who haven’t taken an NTRK inhibitor before.
Guangzhou, GuangdongAges 2 years+ - NCT05711992Recruiting
Registry for rare brain embryonal tumors in children and teens
This study is an international registry (a way to collect medical information) for people with certain rare brain tumors, diagnosed since 2010. It helps researchers understand these tumors better, which can guide future treatments.
YerevanAges 1 day–25 years - NCT05681195RecruitingPhase 2
Zanubrutinib plus pemetrexed for recurrent brain lymphomas
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Miami, FloridaAges 18 years+ - NCT05672043Recruiting
Study genetic risks in children with malignant brain tumors
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
Beijing, Beijing MunicipalityAges birth–18 years - NCT07698899RecruitingPhase 1
Study of a new treatment for childhood brain and CNS cancers
This trial tests a radioactive drug (177Lu-DTPA-Omburtamab) given directly into the fluid around the brain for children and teens with certain brain cancers or cancers that have spread to the central nervous system. It aims to see if this treatment is safe and effective for tumors that have come back or not responded to other therapies.
Basking Ridge, New JerseyAges 3–22 - NCT05386108RecruitingPhase 1/Phase 2
Test abemaciclib plus elacestrant for breast cancer brain spread
This trial studies whether the combination of abemaciclib and elacestrant can slow or shrink ER-positive, HER2-negative breast cancer that has spread to the brain. It is designed for people whose cancer has progressed despite prior hormone (endocrine) treatment.
Fullerton, CaliforniaAges 18 years+ - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT05209620RecruitingPhase 2
Orelabrutinib plus pemetrexed for lymphoma in the brain
This Phase 2 trial tests a combination medicine (orelabrutinib with pemetrexed) to treat lymphoma that has returned or is not responding, specifically in the brain or spinal fluid. If you qualify, the goal is to shrink measurable tumors and improve control of central nervous system lymphoma.
Zhengzhou, HenanAges 18–75 - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT02530658Recruiting
Sequencing children’s tumor and normal tissue samples
This study collects children’s normal and tumor tissue (or blood-related normal samples) and reads their DNA/RNA to look at genetic information. It may help researchers understand cancer-related changes and improve future testing, even when the goal isn’t to treat you directly.
Memphis, TennesseeAges Any age - NCT04852354Recruiting
Donate brain/spinal tumor tissue for drug testing
This study collects leftover brain or spinal tumor tissue during neurosurgery (or from autopsies) so researchers can test drugs and measure how they work. It may help future treatments by improving drug screening using real patient tissue.
New York, New YorkAges Any age - NCT04737889RecruitingPhase 2
Rituximab plus lenalidomide, methotrexate, and temozolomide for brain lymphoma
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
Zhengzhou, HenanAges 18–70 - NCT04684368RecruitingPhase 2
New treatment for children and young adults with a brain tumor
This trial tests a new treatment approach for a rare brain tumor called NGGCT. It aims to see if a different way of treating the tumor can be effective and safe for children and young adults.
Birmingham, AlabamaAges 3–29 - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT04516720Recruiting
Build a database of brain and spinal cord tumor cases
This study builds a large medical database of people with primary brain or spinal cord tumors treated at the Montpellier Cancer Institute. It may help researchers understand patterns of care and outcomes, which can guide future research and treatment decisions.
Montpellier, HeraultAges 18 years+ - NCT04475640Recruiting
Genetic testing study for cancer patients in different ethnic groups
This study looks at cancer-related inherited gene changes using blood samples. It may help patients and doctors understand cancer risk and guide treatment planning, especially across different ethnic communities.
Scottsdale, ArizonaAges 18 years+
Hear when a new Central Nervous System Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for central nervous system tumor?
- Yes. Clin2 currently lists 95 recruiting central nervous system tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a central nervous system tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a central nervous system tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.